TCGA-CR-7385-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.530
- G2M_CHECKPOINT+0.420
- SPERMATOGENESIS+0.310
- ALLOGRAFT_REJECTION+0.270
- FATTY_ACID_METABOLISM+0.190
- INTERFERON_GAMMA_RESPONSE+0.110
- MITOTIC_SPINDLE+0.110
- XENOBIOTIC_METABOLISM+0.110
- CHOLESTEROL_HOMEOSTASIS+0.090
- ANDROGEN_RESPONSE+0.070
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.600
- ANGIOGENESIS-0.560
- MYOGENESIS-0.470
- HEDGEHOG_SIGNALING-0.360
- TGF_BETA_SIGNALING-0.360
- MYC_TARGETS_V2-0.340
- PANCREAS_BETA_CELLS-0.330
- APICAL_JUNCTION-0.310
- WNT_BETA_CATENIN_SIGNALING-0.310
- COAGULATION-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CR-5248-01A-01R-2016-07 | — | — | 0.869 |
| 2 | SRR12202422 | — | — | 0.831 |
| 3 | SRR8392881 | — | cohortSQ1 | 0.822 |
| 4 | TCGA-QK-A6V9-01A-11R-A34R-07 | — | — | 0.809 |
| 5 | TCGA-CR-7404-01A-11R-2132-07 | — | — | 0.800 |
| 6 | TCGA-CV-5443-01A-01R-1514-07 | — | — | 0.783 |
| 7 | TCGA-P3-A5Q5-01A-11R-A28V-07 | — | — | 0.779 |
| 8 | C3L-01000 | — | cohortA4 | 0.779 |
| 9 | SRR12202426 | — | — | 0.775 |
| 10 | ULC0583T_S75 | — | cohortA1 | 0.769 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.310 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.110 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.110 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.110 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.090 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.070 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.070 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.070 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.050 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.050 | Inavolisib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.030 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |